Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (91-100 of 858) with videos related to

Pageof 86
Sort By:
Current Opinion in Cardiology|October 20, 2005
Optimal goals for statin use in patients with coronary artery diseaseKausik K Ray, Christopher P Cannon
Lancet (London, England)|June 1, 2017
STREAM characterisation correction - Authors' replyGrant W Reed, Christopher P Cannon
Clinical Cardiology|July 23, 2013
Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stentingGrant W Reed, Christopher P Cannon
Clinical Cardiology|March 8, 2018
PCSK9 inhibitor valuation: A science-based review of the two recent modelsSeth J Baum, Christopher P Cannon
Circulation|June 2, 2005
Treatment of elevated cholesterolBenjamin M Scirica, Christopher P Cannon
The American Journal of Cardiology|December 25, 2007
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potentialBenjamin A Steinberg, Christopher P Cannon
Current Opinion in Lipidology|November 6, 2004
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biologyKausik K Ray, Christopher P Cannon
The American Journal of Cardiology|November 14, 2006
Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapyChristopher P Cannon, Dalton S McLean
The American Journal of Cardiology|December 16, 2006
Clinical trials update from the annual scientific session of the American College of Cardiology 2006Christopher P Cannon, Deepak L Bhatt
Journal of the American College of Cardiology|May 16, 2006
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factorsEli V Gelfand, Christopher P Cannon
Pageof 86

Showing results (91-100 of 858) with videos related to

Sort By:
Pageof 86
Current Opinion in Cardiology|October 20, 2005
Optimal goals for statin use in patients with coronary artery diseaseKausik K Ray, Christopher P Cannon
Lancet (London, England)|June 1, 2017
STREAM characterisation correction - Authors' replyGrant W Reed, Christopher P Cannon
Clinical Cardiology|July 23, 2013
Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stentingGrant W Reed, Christopher P Cannon
Clinical Cardiology|March 8, 2018
PCSK9 inhibitor valuation: A science-based review of the two recent modelsSeth J Baum, Christopher P Cannon
Circulation|June 2, 2005
Treatment of elevated cholesterolBenjamin M Scirica, Christopher P Cannon
The American Journal of Cardiology|December 25, 2007
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potentialBenjamin A Steinberg, Christopher P Cannon
Current Opinion in Lipidology|November 6, 2004
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biologyKausik K Ray, Christopher P Cannon
The American Journal of Cardiology|November 14, 2006
Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapyChristopher P Cannon, Dalton S McLean
The American Journal of Cardiology|December 16, 2006
Clinical trials update from the annual scientific session of the American College of Cardiology 2006Christopher P Cannon, Deepak L Bhatt
Journal of the American College of Cardiology|May 16, 2006
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factorsEli V Gelfand, Christopher P Cannon
Pageof 86